Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00541
|
|||||
Drug Name |
Loratadine
|
|||||
Synonyms |
1-Piperidenecarboxylic acid, 4-(8-chloro-5,6-duhydro-11H-benzo [5,6]cyclohepta[1,2-b]-pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-, ethyl ester; 1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester; 1-piperidinecarboxylic acid,4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-,ethyl ester; 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester; 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acidethyl ester; 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cycloheptal[1,2-b]pyridin-11-ylidene-1-piperidinecarboxylic acid ethyl ester; Aerotina; Alarin; Alavert; Alavert (TN); Alavert, Claritin, Loratadine; Alerpriv; AllergyX (TN); Allertidin; Anhissen; Bedix Loratadina; Biloina; Bonalerg; Children's Claritin; Civeran; Claratyne; Claratyne Cold; Claratyne Decongestant; Clarinase; Clarinase Reperabs; Claritin; Claritin (TN); Claritin D; Claritin Hives Relief; Claritin Hives Relief Reditab; Claritin Reditabs; Claritin reditab; Claritin-D (TN); Claritine (TN); Claritine;Clarityn; Clarityn (TN); Clarityne; Clarityne (TN); Clarityne Dy Repetabs; Clarityne-D; Clarium; Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate;Ethyl 4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate; Flonidan (TN); Fristamin; Fristamin (TN); Histaloran; L 9664; Lergy; Lertamine; Lesidas; Lisino; Lomilan (TN); Loracert; Loradex; Loradif; Loranox; Lorantis; Lorastine; Loratadina; Loratadina [Spanish]; Loratadine (JAN/USAN/INN); Loratadine Redidose; Loratadine Wyeth Brand; Loratadine [USAN:BAN:INN]; Loratadinum; Loratadinum [Latin]; Loratidine; Loratyne; Loraver; Lorfast; Lorfast (TN); Loritine; Lowadina; Nularef; Optimin; Polaratyne; Pylor; Restamine; Rhinase; Rinolan (TN); Rinomex; Roletra; Roletra (TN); Sanelor; Sch 29851; Sch-29851; Sch29851; Sensibit; Sinhistan Dy; Sohotin; Symphoral (TN); Tadine; Talorat Dy; Tidilor (TN); Velodan; Versal; Wyeth Brand of Loratadine; Zeos
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Allergy [ICD11: 4A8Z] | Approved | [1] | |||
Therapeutic Class |
Antihistamines
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C22H23ClN2O2
|
|||||
Canonical SMILES |
CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1
|
|||||
InChI |
InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3
|
|||||
InChIKey |
JCCNYMKQOSZNPW-UHFFFAOYSA-N
|
|||||
CAS Number |
CAS 79794-75-5
|
|||||
Pharmaceutical Properties | Molecular Weight | 382.9 | Topological Polar Surface Area | 42.4 | ||
Heavy Atom Count | 27 | Rotatable Bond Count | 2 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 3 | |||
XLogP |
5.2
|
|||||
PubChem CID | ||||||
PubChem SID |
11111394
, 11113345
, 11335967
, 11361206
, 11364390
, 11366952
, 11369514
, 11371620
, 11373832
, 11377676
, 11445825
, 11462178
, 11485284
, 11489400
, 11490556
, 11491992
, 11495310
, 11528699
, 1197563
, 12013131
, 14804759
, 17405241
, 24278525
, 25623638
, 26612522
, 26680506
, 26719690
, 26747010
, 26751528
, 29223071
, 46386837
, 46507853
, 47365230
, 48035159
, 48110481
, 48110482
, 48259268
, 48416183
, 4964188
, 49835216
, 49846690
, 50100268
, 50104102
, 50104103
, 535878
, 7847430
, 7979793
, 8150042
, 8152484
, 855843
|
|||||
ChEBI ID |
CHEBI:6538
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | Loratadine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos. 2003 Mar;31(3):312-8. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.